[go: up one dir, main page]

CN116003445A - 一类烷基锌试剂及其制备方法与应用 - Google Patents

一类烷基锌试剂及其制备方法与应用 Download PDF

Info

Publication number
CN116003445A
CN116003445A CN202310058778.7A CN202310058778A CN116003445A CN 116003445 A CN116003445 A CN 116003445A CN 202310058778 A CN202310058778 A CN 202310058778A CN 116003445 A CN116003445 A CN 116003445A
Authority
CN
China
Prior art keywords
alkyl
reagent
nmr
cdcl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202310058778.7A
Other languages
English (en)
Other versions
CN116003445B (zh
Inventor
李�杰
林杰
陈开鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou University
Original Assignee
Suzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou University filed Critical Suzhou University
Priority to CN202310058778.7A priority Critical patent/CN116003445B/zh
Priority to PCT/CN2023/078633 priority patent/WO2024152408A1/zh
Publication of CN116003445A publication Critical patent/CN116003445A/zh
Application granted granted Critical
Publication of CN116003445B publication Critical patent/CN116003445B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C07B37/02—Addition
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C67/347—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/65—Halogen-containing esters of unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/75—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of acids with a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一类烷基锌试剂及其制备方法与应用，属于合成有机化学技术领域。本发明所述烷基锌试剂的结构通式：R‑znOPiv·Mg(OPiv)Br，其中，R选自链状烷基，环状烷基或取代烷基。本发明通过锂盐催化或者碘单质催化，完成格式试剂的制备，再通过转金属化和无机盐活化策略完成锌试剂的制备进而合成烷基取代的烷基二氟试剂，上述烷基取代的烷基二氟试剂的结构通式：
Figure DDA0004060912350000011
其中，R1选自酯基、烷基、炔基、酰胺、苯并恶唑、磷酸二乙酯或全氟取代烷基；R选自链状烷基、环状烷基或含取代烷基；R2，R3独立选自有取代的烷基；R4选自酯基。所述烷基锌试剂应用于烯烃的双官能团反应中，以及烷基取代的烷基二氟试剂在点击化学反应中得到应用。

Description

一类烷基锌试剂及其制备方法与应用
技术领域
本发明属于合成有机化学技术领域，尤其是一类烷基锌试剂及其制备方法与应用。
背景技术
选择性将氟原子或含氟基团安装到生物活性分子中，其作用为能够独特地调节溶解度、代谢稳定性和生物利用度。例如，CF2基团是各种化合物的一个非常重要的结构基序，具有与农业化学和药物化学相关的活性。因此，现有技术对能够有效引入CF2的方法的需求持续强烈。近年来，通过连续C–C键形成烯烃的选择性二碳官能化已经得到了广泛的关注。然而，迄今为止，在烯烃之间形成两个新的Csp3部分的双重Csp3–Csp3交叉偶联是较难实现的，这可归因于(1)过渡金属物种被阻碍氧化添加到烷基–X键中；(2)新形成的Csp3–[M]中间体的β-H容易消除的倾向；(3)区域选择性和位点选择性的控制。
本发明通过无机盐活化的策略，完成对烷基锌试剂的制备，因该类烷基锌试剂卓越的反应活性，将其应用于烯烃双官能团化反应，高效地实现对烷基取代的烷基二氟试剂的合成。
发明内容
为解决上述技术问题，本发明提供了一种烷基锌试剂及其制备方法与应用。本发明通过锂盐催化或者碘单质催化，完成格式试剂的制备，再通过转金属化和无机盐活化策略完成锌试剂的制备以及合成烷基取代的烷基二氟试剂。本发明通过阴离子调节策略设计新型烷基锌试剂，为新型有机锌试剂开辟了一个前景。
本发明通过以下技术方案实现：
本发明第一个目的是提供一类烷基锌试剂，所述烷基锌试剂的结构通式：R-ZnOPiv·Mg(OPiv)Br；其中，R选自链状烷基、环状烷基和取代烷基中的一种或多种。
在本发明的一个实施例中，所述烷基锌试剂选自以下化合物之一：
Figure BDA0004060912330000021
Figure BDA0004060912330000031
本发明第二个目的是提供所述的烷基锌试剂的制备方法，包括以下步骤：
(1)在有机溶剂中，将烷基溴代物、镁与催化剂混合反应，得到格式试剂；
(2)向步骤(1)所得格式试剂中加入特戊酸锌混合反应，得到所述的烷基锌试剂；其中，Zn(OPiv)2的结构式为
Figure BDA0004060912330000032
在本发明的一个实施例中，所述烷基溴代物选自链状烷基溴代物、环状烷基溴代物和取代烷基溴代物中的一种或多种。
在本发明的一个实施例中，所述催化剂为碘和/或锂盐。
在本发明的一个实施例中，所述碘为碘粒；所述碘粒的个数为1-2粒。
在本发明的一个实施例中，所述有机溶剂选自乙腈、四氢呋喃、N,N-二甲基甲酰胺、1,4-二氧六环和N-甲基吡咯烷酮中的一种或多种。
在本发明的一个实施例中，所述格式试剂与特戊酸锌的摩尔比为1:1.2-1:1.5。
在本发明的一个实施例中，步骤(1)中，所述混合反应条件：反应时间0.5h-2h，反应温度为23℃-60℃。
在本发明的一个实施例中，步骤(2)中，所述混合反应条件：反应时间10min-30min，反应温度为0℃-40℃。
本发明第三个目的是提供所述的烷基锌试剂在烯烃双官能团化反应中的应用。
本发明第四个目的是提供所述的烷基锌试剂在制备烷基取代的烷基二氟试剂中的应用。
在本发明的一个实施例中，所述烷基取代的烷基二氟试剂的制备包括以下步骤：
在有机溶剂中，将
Figure BDA0004060912330000041
与R-ZnOPiv·Mg(OPiv)Br在催化剂作用下混合反应，得到所述烷基取代的烷基二氟试剂，其中X＝Br、I；
其中，R1选自酯基、烷基、炔基、酰胺、苯并恶唑、磷酸二乙酯和全氟取代烷基中的一种或多种；R选自链状烷基、环状烷基和取代烷基中的一种或多种；R2和R3均独立的选自取代烷基；R4选自酯基。
在本发明的一个实施例中，所述
Figure BDA0004060912330000042
与R-ZnOPiv·Mg(OPiv)Br的摩尔比为1:1:1.5-1:2:3，其中X＝Br、I。
在本发明的一个实施例中，所述催化剂选自Co、Fe、Cr、Ni和Cu中的一种或多种。
在本发明的一个实施例中，混合反应的条件：反应温度为0℃-23℃，反应时间为1h-16h。
在本发明的一个实施例中，所述烷基取代的烷基二氟试剂选自以下化合物之一：：
Figure BDA0004060912330000043
Figure BDA0004060912330000044
Figure BDA0004060912330000051
Figure BDA0004060912330000061
本发明的第五个目的是提供所述烷基取代的烷基二氟试剂在click反应中应用。
本发明的技术方案相比现有技术具有以下优点：
本发明所述的新型OPiv负载的烷基锌试剂的制备方法是首次报道，该试剂在无导向基团钴催化的二氟烷基化反应中显示出独特的反应性，从而通过级联Csp3–Csp3/Csp3-Csp3键在双键上实现CF2和Csp3基团的模块化安装，同时完成立体构型保持。特别值得注意的是对烷基锌试剂的显著OPiv调节效应，这导致在其他卤化物负载的有机锌中具有优异的反应性。本发明制备所得烷基锌试剂为固体试剂，与传统的液体试剂(不稳定)相比，本发明制备的烷基锌试剂具有更高的稳定性，且使用方便。此外，通过1,2-选择性二碳官能化的合成简单性和实用性完成对类药物分子和天然产物的简单修饰以及氟化产物的后期衍生得到了很好的说明。本发明通过阴离子调节策略设计新型烷基锌试剂，为新型有机锌试剂开辟了一个前景。
附图说明
为了使本发明的内容更容易被清楚的理解，下面根据本发明的具体实施例并结合附图，对本发明作进一步详细的说明，其中，
图1是本发明实施例1和实施例2中烷基取代的烷基二氟试剂的制备可行性说明；
图2是本发明实施例1中烷基锌试剂的外形图；
图3是本发明实施例1和实施例2中烷基锌试剂及烷基取代的烷基二氟试剂的制备方法；
图4是本发明烷基锌试剂及烷基取代的烷基二氟试剂的反应性；
图5是本发明烷基锌试剂及烷基取代的烷基二氟试剂的反应性；
图6是本发明在应用例中烷基取代的烷基二氟试剂在后续结构修饰及click反应中的合成应用实例。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明，以使本领域的技术人员可以更好地理解本发明并能予以实施，但所举实施例不作为对本发明的限定。
实施例1烷基锌试剂R-ZnOPiv·Mg(OPiv)Br的合成
本实施例提供了一种烷基锌试剂的合成方法，具体如下：
在25mL干燥和充满惰性气体(N2)的反应管中加入Mg(182mg,1.5eq),一粒I2和超干THF(5mL)，将(取代)烷基溴代物(5mmol,1.0eq)在微沸条件下逐滴加入，然后在油浴60℃下搅拌1h，得到相应的格式试剂，根据Kofron的方法，用碘滴定格式试剂并计算浓度，按照格式试剂浓度的1.2倍加入Zn(OPiv)2，并将反应混合物在室温搅拌15min，即得到相应的烷基锌试剂，如图3所述3a-I。其中，烷基溴代物的结构式：
Figure BDA0004060912330000081
实施例2-14烷基锌试剂R-ZnOPiv·Mg(OPiv)Br的合成
本实施例提供了一种烷基锌试剂的合成方法，具体如下：
在25mL干燥和充满惰性气体(N2)的反应管中加入Mg(182mg,1.5eq),一粒I2和超干THF(5mL)，将(取代)烷基溴代物(5mmol,1.0eq)在微沸条件下逐滴加入，然后在油浴60℃下搅拌1h，得到相应的格式试剂，根据Kofron的方法，用碘滴定格式试剂并计算浓度，按照格式试剂浓度的1.2倍加入Zn(OPiv)2，并将反应混合物在室温搅拌15min，即得到相应的烷基锌试剂。其中，烷基溴代物的结构式：
Figure BDA0004060912330000082
Figure BDA0004060912330000083
其中，由烷基溴代物
Figure BDA0004060912330000091
制备所得烷基锌试剂
Figure BDA0004060912330000092
(附图中缩写为
Figure BDA0004060912330000093
)如图2所示。由图2可以看出，本发明制备所得烷基锌试剂为固体。
实施例15烷基锌试剂R-ZnOPiv·Mg(OPiv)Br的合成
在25mL干燥和充满惰性气体(N2)的反应管中加入Mg(2.4eq),干燥的LiCl(1.25eq)，Zn(OPiv)2(1.1eq)超干THF(1mol/mL相当于所用溴代物)，将相应的溴代物(1.0eq)在0℃加入上述溶液，然后该反应液在室温下搅拌5h，即得到相应的烷基锌试剂。其中，烷基溴代物的结构式：
Figure BDA0004060912330000094
对比例1
本对比例提供了一种烷基锌试剂的合成方法，具体方法如下：
在25mL干燥和充满惰性气体(N2)的反应管中加入1.2eq的1M的ZnCl2溶液，加入1mLTHF，然后加入实施例1中相同方法制备的1.0eq的格式试剂，搅拌15min后，即得到相应化合物，如图3所示3a-II。
对比例2
本对比例提供了一种烷基锌试剂的合成方法，具体方法如下：
在25mL干燥和充满惰性气体(N2)的反应管中加入1.2eq的干燥的ZnBr2固体，加入1mL THF，然后加入实施例1中相同方法制备的1.0eq的格式试剂，搅拌15min后，得到相应化合物，如图2所示3a-III。
对比例3
本对比例提供了一种烷基锌试剂的合成方法，具体方法如下：
在25mL干燥和充满惰性气体(N2)的反应管中加入1.2eq的干燥的ZnI2固体，加入1mL THF，然后加入实施例1中相同方法制备的1.0eq的格式试剂，搅拌15min后，得到相应化合物，如图3所示3a-IV。
对比例4
在25mL干燥和充满惰性气体(N2)的反应管中加入0.5eq的Zn(OPiv)2固体，加入1mLTHF，然后加入实施例1中相同方法制备的1.0eq格式试剂，搅拌15min后，得到相应化合物，如图3所示3a-V。
对比例5
在25mL干燥和充满惰性气体(N2)的反应管中加入0.5eq的ZnCl2固体，加入1mLTHF，然后加入实施例1中相同方法制备的1.0eq的格式试剂，搅拌15min后，即得到相应化合物，如图3所示3a-VI。
应用例烷基取代的烷基二氟试剂化合物的合成
将实施例1-15中所得R-ZnOPiv·Mg(OPiv)Br(附图中缩写为R-ZnOPiv)分别与
Figure BDA0004060912330000101
反应混合，得到
Figure BDA0004060912330000102
其中，X＝Br、I，具体反应条件见图3-5，R选自链状烷基、环状烷基或含取代烷基；R1选自酯基、烷基、炔基、酰胺、苯并恶唑、磷酸二乙酯或全氟取代烷基；R选自链状烷基、环状烷基或含取代烷基；R2，R3独立选自有取代的烷基；R4选自酯基。反应所得产物见图4和图5，由图4和图5可知，使用本发明所得烷基锌试剂在过渡金属钴催化烯烃的双官能团化反应中的应用，产物具有较高的收率。
测试例
将实施例1和对比例1-5制备的6中不同的烷基锌试剂在相同的条件下通过烯烃的双官能团化反应制备烷基取代的烷基二氟试剂。利用气相色谱内标法获得产物产率分别是78％、16％、11％、20％、37％和15％，即如图3所示。
由此可见，实施例1的效果最好，即该类烷基锌试剂反应性更优。对比例4，5加入的Zn盐与格式试剂摩尔比是1：2的关系，与实施例1和对比例1加入的摩尔比不同，生成化合物结构如3a-V，3a-VI所示，这类二倍体的结构反应性不如3a-I。
为了进一步测试上述烷基锌试剂的反应性，设计了本发明烷基锌试剂在过渡金属钴催化烯烃的双官能团化反应。通过对催化体系的反应条件筛选后进行系统的反应动力学监测，实验结果表明该类烷基锌试剂在反应性方面表现出了明显的优越性，以高转化率得到目标产物，具体如图3示，所得化合物4-化合物49核磁表征结果如下所示。
化合物4-化合物49的核磁表征数据：
Ethyl
2-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)cyclohex-1-ene-1-carboxylate(4)
1H-NMR(400MHz,CDCl3):δ＝4.30(q,J＝7.1,2H),4.17(qd,J＝7.1,2.0,2H),3.50–3.41(m,1H),2.32–2.24(m,2H),2.23–1.91(m,4H),1.64–1.56(m,4H),1.49(dt,J＝13.1,6.6,1H),1.44–1.37(m,2H),1.35(t,J＝7.2,3H),1.29(t,J＝7.1,3H),1.16(ddt,J＝12.4,10.6,6.3,1H),1.04(tdd,J＝13.2,8.7,6.0,1H),0.86(dd,J＝6.6,2.2,6H).13C-NMR(100MHz,CDCl3):δ＝169.5,164.2(t,2JC-F＝32.7),145.1,127.5,116.2(t,1JC-F＝251.0),62.8,60.1,37.6(t,2JC-F＝22.1),36.2,35.5(t,3JC-F＝3.2),31.1,28.0,27.2,23.9,22.7,22.4,22.2,22.0,14.2,13.9.19F-NMR(376MHz,CDCl3):δ＝-103.22(d,J＝262.5),-104.09(d,J＝262.4).HR-MS(EI)m/z calcd for C20H32F2O4[M+H+]375.2341,found 375.2345.
Ethyl
8-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-car boxylate(5)
1H-NMR(400MHz,CDCl3):δ＝4.33–4.26(m,2H),4.17(tt,J＝7.2,3.6,2H),4.02–3.93(m,4H),3.76–3.68(m,1H),2.52(q,J＝17.7,2H),2.33–2.04(m,4H),1.72(t,J＝6.5,2H),1.57–1.37(m,3H),1.34(t,J＝7.2,3H),1.28(t,J＝7.1,3H),1.21–1.11(m,1H),1.11–1.00(m,1H),0.86(d,J＝6.6,6H).13C-NMR(100MHz,CDCl3):δ＝168.0,164.3(t,2JC-F＝32.8),146.7,124.9,116.2(t,1JC-F＝251.1),107.4,64.6,64.6,62.9,60.4,37.8(t,2JC-F＝22.3),37.4,36.2,34.9(t,3JC-F＝3.3),31.3,30.7,28.1,23.8,22.8,22.5,14.3,14.0.19F-NMR(376MHz,CDCl3):δ＝-103.13(d,J＝262.6),-103.97(d,J＝263.0).HR-MS(EI)m/zcalcd for C22H34F2O6[M+H+]433.2396,found433.2399.
Ethyl
2-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)-5,5-difluorocyclohex-1-ene-1-carbo xylate(6)
1H-NMR(400MHz,CDCl3):δ＝4.30(qd,J＝7.1,1.6,2H),4.19(q,J＝7.1,2H),3.90–3.80(m,1H),2.89–2.72(m,2H),2.43–2.12(m,4H),2.10–1.90(m,2H),1.54–1.37(m,3H),1.34(t,J＝7.2,3H),1.30(t,J＝7.1,3H),1.22–1.12(m,1H),1.06–0.95(m,1H),0.86(dd,J＝6.6,1.6,6H).13C-NMR(100MHz,CDCl3):δ＝167.0,164.1(t,2JC-F＝32.7),147.1,123.1(dd,3JC-F＝6.3,4.4),122.3(t,1JC-F＝238.9),116.0(t,1JC-F＝251.2),63.0,60.8,37.6(t,2JC-F＝22.3),36.3(t,2JC-F＝28.0),36.1,34.6,31.4,29.8(t,2JC-F＝24.3),28.1,22.8,22.5,14.2,14.0.19F-NMR(376MHz,CDCl3):δ＝-95.45(d,J＝235.9),-97.01(d,J＝235.9),-103.09(d,J＝264.7),-104.20(d,J＝264.6).HR-MS(EI)m/z calcd forC20H30F4O4[M+H+]411.2153,found411.2157.
Ethyl
2-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)-5,5-dimethylcyclohex-1-ene-1-carb oxylate(7)
1H-NMR(400MHz,CDCl3):δ＝4.30(qd,J＝7.1,1.2,2H),4.16(qd,J＝7.1,1.9,2H),3.53–3.44(m,1H),2.30–2.15(m,1H),2.15–1.96(m,5H),1.53–1.39(m,3H),1.38–1.32(m,5H),1.29(t,J＝7.1,3H),1.17(ddt,J＝12.3,10.5,6.2,1H),1.10–0.96(m,1H),0.92(d,J＝10.4,6H),0.85(dd,J＝6.6,2.2,6H).13C-NMR(100MHz,CDCl3):δ＝169.7,164.4(t,2JC-F＝32.7),143.7,126.9,116.3(t,1JC-F＝251.1),62.9,60.2,41.0,37.9(t,2JC-F＝22.1),36.46,35.3(t,3JC-F＝3.0),34.9,31.4,28.8,28.6,28.1,27.7,22.9,22.5,21.8,14.3,14.0.19F-NMR(376MHz,CDCl3)δ＝-103.39(d,J＝262.6),-104.21(d,J＝262.6).HR-MS(EI)m/z calcd for C22H36F2O4[M+H+]403.2654,found 403.2657.
Ethyl
4-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)-4'-methoxy-1,2,5,6-tetrahydro-[1,1'-biphenyl]-3-carboxylate(8)
1H-NMR(400MHz,CDCl3):δ＝7.15(d,J＝8.6,2H),6.86(dd,J＝8.7,2.8,2H),4.32(q,J＝7.2,2H),4.17(qdd,J＝7.1,3.5,1.5,2H),3.79(d,J＝1.4,3H),3.62–3.49(m,1H),2.84–2.50(m,2H),2.42–2.04(m,5H),1.95(d,J＝12.6,1H),1.74–1.62(m,1H),1.57–1.39(m,3H),1.36(t,J＝7.1,3H),1.27(td,J＝7.1,2.9,3H),1.23–0.96(m,2H),0.91–0.82(m,6H).13C-NMR(100MHz,CDCl3):δ＝169.2,169.2,164.4(t,2JC-F＝32.8),164.3(t,2JC-F＝32.7),158.2,158.1,145.6,145.0,138.4,138.2,127.9,127.8,127.6,127.3,116.3(t,1JC-F＝251.8),116.3(t,1JC-F＝250.8),114.0,62.9,60.4,55.4,39.2,38.6,38.0(t,2JC-F＝22.2),37.5(t,2JC-F＝22.2),36.4,36.4,35.8,35.5(t,3JC-F＝3.3),35.3(t,3JC-F＝3.2),35.1,31.8,30.9,29.4,29.2,28.2,28.2,25.0,24.3,22.9,22.9,22.6,14.4,14.3,14.1.19F-NMR(376MHz,CDCl3):δ＝-103.10(d,J＝262.5),-103.65(s),-104.07(d,J＝262.7).HR-MS(EI)m/z calcd for C27H38F2O5[M+H+]481.2760,found 481.2764.
Ethyl
2-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)cyclopent-1-ene-1-carboxylate(9)
1H-NMR(400MHz,CDCl3):δ＝4.27(q,J＝7.1,2H),4.18(q,J＝7.1,2H),3.92–3.83(m,1H),2.60(t,J＝7.3,2H),2.51–2.30(m,2H),2.29–2.11(m,2H),1.86–1.73(m,2H),1.56–1.36(m,3H),1.34(dd,J＝9.2,5.1,3H),1.29(t,J＝7.1,3H),1.15(ddd,J＝16.8,12.4,5.9,1H),1.05–0.95(m,1H),0.85(d,J＝6.6,6H).13C-NMR(100MHz,CDCl3):δ＝166.0,164.2(t,2JC-F＝32.7),158.6,129.9,116.1(t,1JC-F＝251.0),62.9,59.9,38.1(t,2JC-F＝22.4),36.3,33.9,32.9,32.4(t,3JC-F＝3.7),31.9,28.0,22.8,22.5,21.7,14.4,14.0.19F-NMR(376MHz,CDCl3):δ＝-103.35(s),-103.38(s).HR-MS(EI)m/z calcd for C19H30F2O4[M+H+]361.2185,found361.2188.
Methyl
2-(1-ethoxy-2,2-difluoro-7-methyl-1-oxooctan-4-yl)cyclohept-1-ene-1-carboxylate(10)
1H-NMR(400MHz,CDCl3):δ＝4.34–4.26(m,2H),3.70(s,3H),3.36–3.27(m,1H),2.49–2.34(m,2H),2.22–2.03(m,4H),1.82–1.69(m,2H),1.61–1.38(m,7H),1.35(t,J＝7.1,3H),1.21–1.02(m,2H),0.86(dd,J＝6.6,2.5,6H).13C-NMR(100MHz,CDCl3):δ＝170.7,164.3(t,2JC-F＝32.9),151.3,133.2,116.3(t,1JC-F＝251.2),62.9,51.4,37.5(t,2JC-F＝22.1),36.7(t,3JC-F＝3.4),36.5,32.6,31.1,28.9,28.1,26.4,26.3,22.8,22.6,14.0.19F-NMR(376MHz,CDCl3):δ＝-102.77(d,J＝262.6),-103.60(d,J＝262.8).HR-MS(EI)m/zcalcd for C20H32F2O4[M+H+]375.2341,found 375.2339.
Diethyl(Z)-2-butyl-6,6-difluoro-4-isopentyl-3-methylhept-2-enedioate(11)
1H-NMR(400MHz,CDCl3):δ＝4.29(q,J＝7.1,2H),4.23–4.12(m,2H),3.25(tt,J＝8.5,5.7,1H),2.29–2.01(m,4H),1.62(s,3H),1.46(ddd,J＝17.4,12.1,6.1,2H),1.39–1.31(m,7H),1.29(t,J＝7.1,4H),1.15(ddd,J＝16.9,12.5,5.9,1H),1.01(tdd,J＝11.0,7.5,3.4,1H),0.89(t,J＝7.1,3H),0.85(dd,J＝6.6,2.4,6H).13C-NMR(100MHz,CDCl3):δ＝170.0,164.3(t,2JC-F＝32.7),141.5,131.5,116.2(t,1JC-F＝251.0),62.9,60.2,37.8(t,2JC-F＝22.2),36.7(t,3JC-F＝3.3),36.3,31.2,30.6,30.2,28.1,22.8,22.6,22.5,14.3,14.0,14.0,12.9.19F-NMR(376MHz,CDCl3):δ＝-103.14(d,J＝263.5),-103.98(d,J＝263.1).HR-MS(EI)m/z calcd for C21H36F2O4[M+H+]391.2654,found 391.2650.
Diethyl
(Z)-2-((R)-3,7-dimethyloct-6-en-1-yl)-6,6-difluoro-4-isopentyl-3-methylhept-2-enedioate(12)
1H-NMR(400MHz,CDCl3):δ＝5.09(t,J＝7.1,1H),4.29(q,J＝7.1,2H),4.22–4.12(m,2H),3.28(ddd,J＝14.1,8.4,5.7,1H),2.33–2.13(m,3H),2.13–1.88(m,3H),1.68(s,3H),1.63(s,3H),1.60(s,3H),1.52–1.37(m,4H),1.34(t,J＝7.2,4H),1.28(t,J＝7.1,4H),1.23–1.10(m,3H),1.06–0.96(m,1H),0.89(d,J＝6.4,3H),0.85(dd,J＝6.6,2.3,6H).13C-NMR(100MHz,CDCl3):δ＝169.9,169.9,164.3(t,2JC-F＝33.1),141.7,141.7,131.5,131.2,125.0,116.2(t,1JC-F＝251.2),62.9,60.2,37.8(t,2JC-F＝22.3),37.0,37.0,36.6(t,3JC-F＝2.8),36.3,35.4,35.4,32.6,31.2,28.1,28.1,25.9,25.7,22.9,22.5,19.6,19.6,17.8,14.4,14.0,12.9.19F-NMR(376MHz,CDCl3):δ＝-103.14(d,J＝263.4),-103.15(d,J＝263.3),-103.89(d,J＝263.1),-103.91(d,J＝263.6).HR-MS(EI)m/z calcd forC27H46F2O4[M+H+]473.3437,found473.3440.
Diethyl
(Z)-6,6-difluoro-4-isopentyl-3-methyl-2-(2-(thiophen-3-yl)ethyl)hept-2-enedioate(13)
1H-NMR(400MHz,CDCl3):δ＝7.22(dd,J＝4.7,3.1,1H),6.97–6.90(m,2H),4.34–4.25(m,2H),4.22–4.13(m,2H),3.34(tt,J＝8.4,5.7,1H),2.76–2.68(m,2H),2.60–2.53(m,2H),2.24–2.03(m,2H),1.54(s,3H),1.47(dd,J＝13.2,6.5,1H),1.43–1.37(m,1H),1.34(dd,J＝8.7,5.6,4H),1.30(t,J＝7.1,3H),1.20–1.10(m,1H),1.03–0.94(m,1H),0.86(dd,J＝6.6,4.0,6H).13C-NMR(100MHz,CDCl3):δ＝169.6,164.3(t,2JC-F＝32.8),143.6,142.0,130.1,128.5,125.3,120.6,116.2(t,1JC-F＝251.1),62.9,60.4,37.7(t,2JC-F＝22.2),36.2,36.6(t,3JC-F＝3.2),31.7,31.2,29.0,28.1,22.8,22.5,14.3,14.0,13.0.19F-NMR(376MHz,CDCl3):δ＝-103.58(s),-103.60(s).HR-MS(EI)m/z calcd for C23H34F2O4S[M+H+]445.2219,found445.2222.
Diethyl
(Z)-6,6-difluoro-4-isopentyl-2-(3-(4-methoxyphenoxy)propyl)-3-methylhept-2-enedioate(14)
1H-NMR(400MHz,CDCl3)：δ＝6.82(s,4H),4.33–4.23(m,2H),4.22–4.11(m,2H),3.94–3.84(m,2H),3.76(s,3H),3.31(tt,J＝8.7,5.7,1H),2.48(dd,J＝10.5,5.0,2H),2.25–2.00(m,2H),1.91–1.79(m,2H),1.64(s,3H),1.44(ddd,J＝17.6,12.2,6.1,2H),1.38–1.30(m,4H),1.28(t,J＝7.1,3H),1.20–1.09(m,1H),1.03–0.92(m,1H),0.83(t,J＝6.6,6H).13C-NMR(100MHz,CDCl3):δ＝169.7,164.3(t,2JC-F＝32.7),153.8,153.3,143.2,130.2,116.2(t,1JC-F＝251.1),115.4,114.7,67.4,62.9,60.4,55.9,37.8(t,2JC-F＝22.1),36.3,31.2,28.1,28.1,26.7,22.8,22.4,14.3,14.0,13.0.19F-NMR(376MHz,CDCl3):δ＝-102.67–-104.38(m,2F).HR-MS(EI)m/z calcd for C27H40F2O6[M+H+]499.2866,found499.2869.
Diethyl
(Z)-2-(4-(4-chloro-3-methylphenoxy)butyl)-6,6-difluoro-4-isopentyl-3-methylhept-2-enedioa te(15)
1H-NMR(400MHz,CDCl3):δ＝7.20(d,J＝8.7,1H),6.75(d,J＝2.9,1H),6.65(dd,J＝8.7,3.0,1H),4.34–4.25(m,2H),4.23–4.12(m,2H),3.90(t,J＝6.4,2H),3.29(tt,J＝8.6,5.7,1H),2.36–2.30(m,5H),2.27–2.02(m,2H),1.81–1.72(m,2H),1.64(s,3H),1.60–1.36(m,5H),1.34(t,J＝7.2,3H),1.28(t,J＝7.1,3H),1.20–1.10(m,1H),1.00(tdd,J＝11.8,8.5,4.9,1H),0.86(d,J＝2.0,3H),0.84(d,J＝1.9,3H).13C-NMR(100MHz,CDCl3):δ＝-169.8,164.3(t,2JC-F＝32.3),157.8,142.4,137.0,130.9,129.7,125.7,117.2,116.2(t,1JC-F＝251.3),113.2,68.0,62.9,60.3,37.7(t,2JC-F＝22.2),36.7,36.3,31.2,30.1,29.0,28.1,24.9,22.8,22.5,20.4,14.3,14.0,13.1.19F-NMR(376MHz,CDCl3):δ＝-103.59(d,J＝6.4).HR-MS(EI)m/z calcd for C28H41ClF2O5[M+H+]531.2683,found 531.2680.
Diethyl(Z)-2-benzyl-6,6-difluoro-4-isopentyl-3-methylhept-2-enedioate(16)
1H-NMR(400MHz,CDCl3):δ＝7.27–7.22(m,2H),7.19–7.13(m,3H),4.34–4.22(m,2H),4.14–4.04(m,2H),3.74–3.62(m,2H),3.55(tt,J＝8.8,5.6,1H),2.34–2.05(m,2H),1.68(s,3H),1.44(tdd,J＝14.4,11.0,5.2,3H),1.34(t,J＝7.2,3H),1.27–1.18(m,1H),1.16(t,J＝7.1,3H),1.05(tdd,J＝12.3,7.0,5.2,1H),0.86(dd,J＝6.6,4.9,6H).13C-NMR(100MHz,CDCl3):δ＝169.1,164.3(t,2JC-F＝32.7),145.7,139.5,129.5,128.4,128.3,126.1,116.2(t,1JC-F＝251.2),62.9,60.3,37.7(t,2JC-F＝22.2),36.4,36.1,31.5,28.1,22.8,22.5,14.2,14.0,13.9.19F-NMR(376MHz,CDCl3):δ＝-102.90(d,J＝263.6),-103.82(d,J＝263.7).HR-MS(EI)m/z calcd for C24H34F2O4[M+H+]425.2498,found425.2501.
Diethyl(Z)-2-(4-chlorobenzyl)-6,6-difluoro-4-isopentyl-3-methylhept-2-enedioate(17)
1H-NMR(400MHz,CDCl3):δ＝7.22(d,J＝8.4,2H),7.10(d,J＝8.5,2H),4.33–4.24(m,2H),4.13–4.05(m,2H),3.66(d,J＝17.0,2H),3.56(tt,J＝8.8,5.4,1H),2.31–2.04(m,2H),1.67(s,3H),1.45(qdd,J＝13.4,8.9,5.5,3H),1.34(t,J＝7.2,3H),1.23–1.13(m,4H),1.09–0.97(m,1H),0.86(dd,J＝6.6,4.1,6H).13C-NMR(100MHz,CDCl3):δ＝168.9,164.2(t,2JC-F＝32.7),146.3,138.0,131.8,129.7,129.1,128.5,116.2(t,1JC-F＝251.1),62.9,60.4,37.7(t,2JC-F＝22.2),36.4,35.5,31.5,28.1,22.8,22.5,14.2,14.0,13.9.19F-NMR(376MHz,CDCl3):δ＝-102.66(d,J＝264.5),-104.17(d,J＝263.7).HR-MS(EI)m/zcalcd for C24H33ClF2O4[M+H+]459.2108,found 459.2114.
Diethyl(Z)-2-(4-bromobenzyl)-6,6-difluoro-4-isopentyl-3-methylhept-2-enedioate(18)
1H-NMR(400MHz,CDCl3):δ＝7.37(d,J＝8.4,2H),7.05(d,J＝8.4,2H),4.33–4.24(m,2H),4.14–4.05(m,2H),3.71–3.51(m,3H),2.33–2.04(m,2H),1.67(d,J＝6.0,3H),1.54–1.36(m,3H),1.34(t,J＝7.2,3H),1.26–1.15(m,4H),1.09–0.97(m,1H),0.86(dd,J＝6.6,4.1,6H).13C-NMR(100MHz,CDCl3):δ＝168.71,164.08(t,2JC-F＝32.7),146.34,138.41,131.33,129.98,128.83,119.74,116.03(t,1JC-F＝251.1),62.81,60.32,37.55(t,2JC-F＝22.2),36.24,35.46,31.39,27.94,22.69,22.41,14.09,13.90,13.83.19F-NMR(376MHz,CDCl3):δ＝-102.64(d,J＝263.9),-104.17(d,J＝264.0).HR-MS(EI)m/z calcdfor C24H33BrF2O4[M+H+]503.1603,found 503.1598.
Ethyl
2-(5-ethoxy-4,4-difluoro-5-oxopentan-2-yl)-5,5-dimethylcyclohex-1-ene-1-carboxylate(19)
1H-NMR(400MHz,CDCl3):δ＝4.31(q,J＝7.1,2H),4.22–4.12(m,2H),3.59(m,1H),2.34–2.18(m,1H),2.16–1.96(m,5H),1.38–1.32(m,5H),1.32–1.27(m,3H),1.11(d,J＝6.9,3H),0.91(d,J＝3.2,6H).13C-NMR(100MHz,CDCl3):δ＝169.6,164.4(t,2JC-F＝32.8),145.6,125.1,116.3(t,1JC-F＝251.3),62.9,60.3,40.7,38.8(t,2JC-F＝22.2),34.9,30.4,28.5,28.1,21.9,19.7,14.3,14.0.19F-NMR(376MHz,CDCl3)δ＝-104.03(d,J＝261.7),-104.80(d,J＝260.9).HR-MS(EI)m/z calcd for C18H28F2O4[M+H+]347.2028,found347.2023.
Ethyl 2-(6-ethoxy-5,5-difluoro-6-oxohexan-3-yl)cyclohex-1-ene-1-carboxylate(20)
1H-NMR(400MHz,CDCl3):δ＝4.33–4.26(m,2H),4.22–4.13(m,2H),3.40(tt,J＝8.8,5.7,1H),2.35–1.90(m,6H),1.65–1.56(m,4H),1.53–1.38(m,2H),1.35(t,J＝7.2,3H),1.29(t,J＝7.1,3H),0.84(t,J＝7.4,3H).13C-NMR(100MHz,CDCl3):δ＝169.7,164.4(t,2JC-F＝32.8),144.7,128.0,116.3(t,1JC-F＝251.0),62.9,60.2,37.5(t,2JC-F＝22.2),37.0(t,3JC-F＝3.3),27.3,26.4,23.9,22.4,22.2,14.3,14.0,11.8.19F-NMR(376MHz,CDCl3):δ＝-103.22(d,J＝263.1),-104.23(d,J＝262.2).HR-MS(EI)m/z calcd forC17H26F2O4[M+H+]333.1872,found333.1877.
Ethyl 8-(9-cyano-5,5-difluorononan-3-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(21)
1H-NMR(400MHz,CDCl3):δ＝4.22–4.13(m,2H),4.04–3.94(m,4H),3.60–3.51(m,1H),2.54(s,2H),2.37(t,J＝7.0,2H),2.25(qd,J＝17.7,8.8,2H),2.08–1.80(m,4H),1.72(dd,J＝13.4,6.7,4H),1.66–1.58(m,2H),1.55–1.37(m,2H),1.29(t,J＝7.1,3H),0.83(t,J＝7.4,3H).13C-NMR(100MHz,CDCl3):δ＝168.5,146.7,125.0,124.8(t,1JC-F＝241.5),119.6,107.4,64.6,60.5,39.7(t,2JC-F＝24.6),37.4,37.1(t,3JC-F＝4.0),35.2(t,2JC-F＝25.4),30.7,27.0,25.3,23.5,21.6(t,3JC-F＝4.6),17.1,14.3,11.8.19F-NMR(376MHz,CDCl3)δ＝-94.30(d,J＝242.7),-95.83(d,J＝242.7).HR-MS(EI)m/z calcd forC21H31F2NO4[M+H+]400.2294,found400.2297.
Ethyl
8-(1-cyano-5,5-difluoro-10,12,12-trimethyltridecan-7-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-car boxylate(22)
1H-NMR(400MHz,CDCl3):δ＝4.21–4.10(m,2H),4.02–3.91(m,4H),3.66–3.52(m,1H),2.57–2.45(m,2H),2.35(t,J＝7.1,2H),2.31–2.18(m,2H),2.07–1.77(m,4H),1.74–1.57(m,6H),1.48–1.30(m,3H),1.27(t,J＝7.1,3H),1.21–0.95(m,4H),0.86(t,J＝4.4,12H).13C-NMR(100MHz,CDCl3):δ＝168.4,168.3,147.4,147.1,124.8(t,1JC-F＝241.6),124.7,124.6,119.6,107.4,107.4,64.6,64.6,60.4,51.5,51.2,40.1(t,2JC-F＝24.4),39.9(t,2JC-F＝24.6),37.4,36.9,36.7,35.7(t,3JC-F＝3.8),35.3(t,2JC-F＝25.5),35.2(t,2JC-F＝25.5),31.8,31.6,31.2,31.2,30.8,30.1,29.5,29.3,25.3,23.7,22.8,22.5,21.6(t,3JC-F＝4.6),17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-95.02(ddd,J＝284.4,242.6,27.5).HR-MS(EI)m/z calcd for C28H45F2NO4[M+H+]498.3389,found 498.3382.
Ethyl
8-(9-cyano-1-cyclohexyl-5,5-difluorononan-3-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(23)
1H-NMR(400MHz,CDCl3):δ＝4.21–4.12(m,2H),4.03–3.93(m,4H),3.63–3.54(m,1H),2.59–2.45(m,2H),2.41–2.33(m,2H),2.32–2.17(m,2H),2.06–1.80(m,4H),1.74–1.58(m,11H),1.49–1.33(m,2H),1.28(t,J＝7.1,3H),1.22–1.00(m,6H),0.90–0.80(m,2H).13C-NMR(100MHz,CDCl3):δ＝168.4,147.3,124.9(t,1JC-F＝241.6),124.5,119.6,107.4,64.6,64.6,60.5,39.9(t,2JC-F＝24.6),37.8,37.4,35.8(t,3JC-F＝3.9),35.2(t,2JC-F＝25.5),34.9,33.6,33.3,31.4,30.8,26.8,26.5,26.5,25.3,23.7,21.6(t,3JC-F＝4.6),17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-94.18(d,J＝242.6),-95.76(d,J＝242.4).HR-MS(EI)m/z calcd for C27H41F2NO4[M+H+]482.3076,found482.3080.
Ethyl
8-(9-cyano-5,5-difluoro-1-(4-fluorophenyl)nonan-3-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carbo xylate(24)
1H-NMR(400MHz,):δ＝7.13–7.06(m,2H),6.97–6.89(m,2H),4.15(q,J＝7.1,2H),4.04–3.94(m,4H),3.78–3.68(m,1H),2.60–2.43(m,4H),2.39–2.27(m,4H),2.11–1.81(m,4H),1.80–1.61(m,8H),1.28(t,J＝7.1,3H).13C-NMR(100MHz,CDCl3):δ＝168.3,162.6,160.1,146.6,137.8,129.8,129.7,125.3,124.7(t,1JC-F＝241.8),119.6,115.2,115.0,107.3,64.7,64.6,60.6,39.9(t,2JC-F＝24.6),37.4,35.8,35.4(t,2JC-F＝25.4),32.8,30.7,27.2,25.3,23.8,21.6(t,3JC-F＝4.6),17.1,14.3.19F-NMR(376MHz,CDCl3):δ＝-95.21(dd,J＝662.5,243.0),-117.83(s).HR-MS(EI)m/z calcd for C27H34F3NO4[M+H+]494.2513,found494.2517.
Ethyl
2-(1-((5R)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)-6-ethoxy-5,5-difluoro-6-oxohexan-3-yl)-5,5-dimethylcyclohex-1-ene-1-carboxylate(25)
1H-NMR(400MHz,CDCl3):δ＝5.15(s,1H),4.30(dd,J＝14.2,7.1,2H),4.22–4.12(m,2H),3.51(s,1H),2.43–1.66(m,16H),1.56–1.41(m,2H),1.37–1.27(m,9H),0.92(d,J＝8.9,6H),0.80(s,3H).13C-NMR(100MHz,CDCl3):δ＝169.5,169.4,164.2(t,2JC-F＝32.7),148.1,148.0,143.4,143.2,127.1,127.1,116.1(t,1JC-F＝251.1),115.9,115.8,62.8,60.2,45.9,45.8,40.9,37.9,37.8(t,2JC-F＝22.2),35.1,34.7,31.7,31.6,31.2,31.1,28.7,28.6,28.4,27.7,27.6,26.3,21.2,14.2,13.9.19F-NMR(376MHz,CDCl3):δ＝-96.91–-109.40(m,).HR-MS(EI)m/z calcd for C28H42F2O4[M+H+]481.3124,found481.3128.
Ethyl
8-(12-cyano-8,8-difluorododec-1-en-6-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(26)
1H-NMR(400MHz,CDCl3):δ＝5.77(ddt,J＝16.9,10.2,6.7,1H),5.04–4.90(m,2H),4.23–4.12(m,2H),4.04–3.92(m,4H),3.71–3.61(m,1H),2.59–2.47(m,2H),2.36(t,J＝7.1,2H),2.24(ddt,J＝17.7,12.8,6.6,2H),2.08–1.80(m,6H),1.75–1.67(m,4H),1.62(dt,J＝8.8,2.8,2H),1.50–1.31(m,3H),1.31–1.26(m,4H).13C-NMR(100MHz,CDCl3):δ＝168.4,147.0,138.8,124.8(t,1JC-F＝241.6),124.8,119.6,114.8,107.4,64.6,60.5,39.9(t,2JC-F＝24.6),37.4,35.4(t,3JC-F＝3.9),35.3(t,2JC-F＝25.4),33.8,33.4,30.7,26.5,25.3,23.7,21.6(t,3JC-F＝4.6),17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-94.33(d,J＝242.8),-95.85(d,J＝242.7).HR-MS(EI)m/z calcd for C24H35F2NO4[M+H+]440.2607,found 440.2611.
Ethyl
8-(8-chloro-1-ethoxy-2,2-difluoro-1-oxooctan-4-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxyl ate(27)
1H-NMR(400MHz,CDCl3):δ＝4.34–4.25(m,2H),4.20–4.13(m,2H),4.02–3.93(m,4H),3.79(dd,J＝13.3,7.1,1H),3.51(t,J＝6.8,2H),2.52(q,J＝17.8,2H),2.33–2.08(m,4H),1.82–1.69(m,4H),1.52–1.37(m,3H),1.34(t,J＝7.2,4H),1.29(t,J＝7.1,3H).13C-NMR(100MHz,CDCl3):δ＝167.9,164.2(t,2JC-F＝32.7),146.2,125.4,116.1(t,1JC-F＝251.2),107.3,64.6,64.6,63.0,60.5,44.9,37.8(t,2JC-F＝22.4),37.4,34.4(t,3JC-F＝3.2),32.7,32.5,30.7,24.3,23.8,14.3,14.0.19F-NMR(376MHz,CDCl3):δ＝-103.08(d,J＝263.3),-104.15(d,J＝263.0).HR-MS(EI)m/z calcd for C21H31ClF2O6[M+H+]453.1850,found453.1855.
Ethyl
2-(9-cyano-1-(1,3-dioxan-2-yl)-5,5-difluorononan-3-yl)cyclohex-1-ene-1-carboxylate(28)
1H-NMR(400MHz,CDCl3):δ＝4.49(t,J＝4.6,1H),4.16(qd,J＝7.1,1.2,2H),4.08(dd,J＝11.5,4.0,2H),3.80–3.68(m,2H),3.43(dd,J＝8.1,5.2,1H),2.36(t,J＝7.0,2H),2.27(s,2H),2.12–1.94(m,4H),1.94–1.78(m,3H),1.70(dd,J＝14.6,7.4,2H),1.66–1.56(m,7H),1.56–1.42(m,4H),1.28(t,J＝7.1,3H).13C-NMR(100MHz,CDCl3):δ＝169.8,145.3,127.6,124.9(t,1JC-F＝241.6),119.6,102.2,67.0,60.3,39.9(t,2JC-F＝24.4),35.9(t,3JC-F＝3.8),35.3(t,2JC-F＝25.5),32.9,27.8,27.3,25.9,25.3,23.8,22.3,22.1,21.6(t,3JC-F＝4.6),17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-94.67(d,J＝242.7),-95.40(d,J＝242.6).HR-MS(EI)m/z calcd for C23H35F2NO4[M+H+]428.2607,found 428.2612.
Ethyl
2-(9-cyano-1-(1,3-dioxan-2-yl)-5,5-difluorononan-3-yl)-5,5-dimethylcyclohex-1-ene-1-carbo xylate(29)
1H-NMR(400MHz,CDCl3)：δ＝4.49(t,J＝4.7,1H),4.20–4.12(m,2H),4.11–4.04(m,2H),3.79–3.68(m,2H),3.44(dd,J＝8.7,5.0,1H),2.36(t,J＝7.0,2H),2.11–1.98(m,6H),1.95–1.79(m,3H),1.75–1.66(m,2H),1.60(ddd,J＝11.2,10.1,6.1,3H),1.56–1.42(m,4H),1.34(dd,J＝7.4,5.2,2H),1.28(t,J＝7.1,3H),0.91(d,J＝9.5,6H).13C-NMR(100MHz,CDCl3):δ＝169.8,143.9,126.9,124.9(t,1JC-F＝241.6),119.6,102.2,67.0,60.3,41.0,40.0(t,2JC-F＝24.5),35.7(t,3JC-F＝3.9),35.3(t,2JC-F＝25.5),34.9,33.0,28.8,28.6,28.2,27.8,25.9,25.3,21.6,17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-95.14(d,J＝3.8).HR-MS(EI)m/z calcd for C25H39F2NO4[M+H+]456.2920,found 456.2926.
Ethyl 8-[1-(4-chlorophenoxy)-11-cyano-7,7-difluoroundecan-5-yl]-1,4-dioxaspiro[4.5]d ec-7-ene-7-carboxylate(30)
1H-NMR(400MHz,CDCl3):δ＝7.24–7.18(m,2H),6.82–6.76(m,2H),4.16(q,J＝7.1Hz,2H),4.02–3.93(m,4H),3.90(t,J＝6.5Hz,2H),3.79–3.61(m,1H),2.53(s,2H),2.36(t,J＝7.0Hz,2H),2.33–2.16(m,2H),2.09–1.81(m,4H),1.78–1.66(m,6H),1.66–1.59(m,2H),1.49(dt,J＝16.6,7.4Hz,2H),1.43–1.33(m,2H),1.26(d,J＝7.1Hz,3H).13C-NMR(100MHz,CDCl3):δ＝168.4,157.8,147.0,129.4,127.2,125.4,124.8(t,1JC-F＝241.6Hz),119.6,115.9,107.4,68.1,64.7,64.6,60.6,39.9(t,2JC-F＝24.7Hz),37.4,35.4(t,2JC-F＝25.5Hz),33.7,30.7,29.2,25.3,23.7,23.6,21.6(t,3JC-F＝4.6Hz),17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-94.47(d,J＝242.8Hz),-96.07(d,J＝242.9Hz).HR-MS(EI)m/zcalcd for C29H38ClF2NO5,[M+H+]554.2479 found 554.2476.
Ethyl
8-(1-(4-chloro-3-methylphenoxy)-11-cyano-7,7-difluoroundecan-5-yl)-1,4-dioxaspiro[4.5]de c-7-ene-7-carboxylate(31)
1H-NMR(400MHz,CDCl3):δ＝7.20(dd,J＝8.7,5.0,1H),6.76(dd,J＝8.1,2.9,1H),6.65(td,J＝8.3,3.0,1H),4.21–4.11(m,2H),4.04–3.93(m,4H),3.92–3.84(m,2H),3.76–3.65(m,1H),2.53(s,2H),2.36(t,J＝7.0,2H),2.33(s,3H),2.27(dd,J＝15.0,6.7,2H),2.08–1.31(m,16H),1.28(td,J＝7.1,4.6,3H).13C-NMR(100MHz,CDCl3):δ＝168.3,157.7,147.0,137.0,129.6,125.7,124.9,124.8(t,2JC-F＝241.6),119.6,117.2,113.2,107.4,68.0,64.6,64.6,60.5,39.9(t,2JC-F＝24.6),37.4,35.4(t,2JC-F＝25.5),33.7,30.7,29.6,29.3,25.9,25.3,23.7,21.6(t,3JC-F＝4.7),20.4,17.1,14.4.19F-NMR(376MHz,CDCl3):δ＝-94.45(d,J＝242.8),-96.05(d,J＝242.9).HR-MS(EI)m/z calcd for C30H40ClF2NO5[M+H+]568.2636,found568.2640.
Ethyl 8-[1-(2-chloro-4-methoxyphenoxy)-11-cyano-7,7-difluoroundecan-5-yl]-1,4-diox aspiro[4.5]dec-7-ene-7-carboxylate(32)
1H-NMR(400MHz,CDCl3):δ＝6.93(d,J＝3.0Hz,1H),6.85(d,J＝9.0Hz,1H),6.73(dd,J＝9.0,3.0Hz,1H),4.17(q,J＝7.1Hz,2H),4.01–3.92(m,6H),3.75(s,3H),3.71(dd,J＝10.2,4.3Hz,1H),2.53(s,2H),2.36(t,J＝7.0Hz,2H),2.31–2.20(m,2H),2.00–1.89(m,2H),1.86–1.68(m,8H),1.65–1.60(m,2H),1.56–1.46(m,2H),1.42(dd,J＝14.2,6.9Hz,2H),1.26(d,J＝7.1Hz,3H).13C-NMR(100MHz,CDCl3):δ＝168.3,153.8,148.9,146.9,124.7,124.7(t,1JC-F＝241.7Hz),123.7,119.5,115.9,115.0,112.9,107.3,69.8,64.5,60.4,55.9,39.8(t,2JC-F＝24.6Hz),37.3,35.3(t,4JC-F＝3.8Hz),35.2(t,2JC-F＝25.4Hz),33.6,30.6,29.2,27.0,25.2,23.6,21.5(t,3JC-F＝4.6Hz),17.0,14.2.19F-NMR(376MHz,CDCl3):δ＝-94.62(d,J＝243.7Hz),-96.13(d,J＝241.8Hz).HR-MS(EI)m/z calcd forC30H40ClF2NO6[M+H+]584.2585,found 584.2588.
Ethyl
8-(7-cyano-1-cyclopropyl-3,3-difluoroheptyl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(33)
1H-NMR(400MHz,CDCl3):δ＝4.18–4.09(m,2H),3.99(pd,J＝7.8,4.3,4H),2.90(td,J＝9.2,5.3,1H),2.54(s,2H),2.51–2.40(m,2H),2.36(t,J＝7.0,2H),2.23–2.02(m,2H),1.96–1.80(m,2H),1.76(t,J＝6.5,2H),1.73–1.67(m,2H),1.66–1.59(m,2H),1.26(t,J＝7.1,3H),0.85–0.74(m,1H),0.65–0.51(m,1H),0.44–0.34(m,1H),0.32–0.15(m,2H).13C-NMR(100MHz,CDCl3):δ＝168.2,148.1,124.5(t,1JC-F＝241.1),123.2,119.6,107.4,64.6,64.6,60.4,40.8,39.7(t,2JC-F＝24.9),37.3,35.3(t,2JC-F＝25.6),30.8,25.2,24.7,21.6,17.0,15.7,14.3,6.4,3.9.19F-NMR(376MHz,CDCl3):δ＝-94.67(d,J＝242.8),-96.03(d,J＝242.7).HR-MS(EI)m/z calcd for C22H31F2NO4[M+H+]412.2294,found 412.2299.
Ethyl
8-(7-cyano-1-cyclobutyl-3,3-difluoroheptyl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(34)
1H-NMR(400MHz,CDCl3):δ＝4.26–4.17(m,2H),4.05–3.91(m,4H),3.63(t,J＝9.1,1H),2.53(s,2H),2.37(t,J＝7.1,2H),2.33–2.02(m,4H),1.94–1.57(m,15H),1.31(t,J＝7.1,3H).13C-NMR(100MHz,CDCl3):δ＝168.6,145.7,125.0,124.7(t,1JC-F＝241.3),119.6,107.4,64.6,64.6,60.5,39.1,37.4,36.5(t,2JC-F＝25.0),34.9(t,2JC-F＝25.4),30.7,28.0,27.1,25.7,25.3,21.5(t,3JC-F＝4.7),17.3,17.0,14.4.19F-NMR(376MHz,CDCl3):δ＝-94.38(d,J＝242.6),-95.37(d,J＝242.6).HR-MS(EI)m/z calcd for C23H33F2NO4[M+H+]426.2450,found426.2448.
Ethyl
8-(1-cyclopropyl-4-(diethylamino)-3,3-difluoro-4-oxobutyl)-1,4-dioxaspiro[4.5]dec-7-ene-7-c arboxylate(35)
1H-NMR(400MHz,CDCl3):δ＝4.11(q,J＝7.1,2H),4.01–3.91(m,4H),3.60–3.21(m,4H),3.03(dd,J＝15.4,8.4,1H),2.56–2.35(m,6H),1.74(t,J＝6.9,2H),1.23(t,J＝7.1,3H),1.14(dt,J＝14.0,7.0,6H),0.87–0.78(m,1H),0.56–0.47(m,1H),0.42–0.32(m,1H),0.31–0.22(m,2H).13C-NMR(100MHz,CDCl3):δ＝168.2,163.0(t,2JC-F＝29.3),148.4,122.8,119.4(t,1JC-F＝255.5),107.5,64.6,64.5,60.2,41.9(t,3JC-F＝6.3),41.6,40.2,37.7(t,2JC-F＝22.6),37.3,30.8,24.9,15.2,14.3,14.2,12.4,6.3,3.8.19F-NMR(376MHz,CDCl3):δ＝-98.26(d,J＝280.2),-99.70(d,J＝280.2).HR-MS(EI)m/z calcd forC22H33F2NO5[M+H+]430.2400,found430.2405.
Ethyl
8-(1-cyclopropyl-3,3-difluoro-4-morpholino-4-oxobutyl)-1,4-dioxaspiro[4.5]dec-7-ene-7-car boxylate(36)
1H-NMR(400MHz,CDCl3):δ＝4.17–4.07(m,2H),4.03–3.94(m,4H),3.76–3.59(m,8H),3.05(dd,J＝16.6,7.1,1H),2.59–2.37(m,6H),1.82–1.69(m,2H),1.27–1.23(t,J＝7.06,3H),0.92–0.74(m,1H),0.60–0.36(m,2H),0.32–0.21(m,2H).13C-NMR(100MHz,CDCl3):δ＝168.1,162.3(t,2JC-F＝29.5),148.2,122.9,119.2(t,1JC-F＝255.4),107.5,66.9,66.8,64.6,64.6,60.3,46.6(t,3JC-F＝6.4),43.5,40.1,37.5(t,2JC-F＝22),37.3,30.8,24.9,15.3,14.3,6.3,3.9.19F-NMR(376MHz,CDCl3):δ＝-97.89(d,J＝282.0),-98.74(d,J＝282.0).HR-MS(EI)m/z calcd for C22H30F2NO6[M+H+]444.2192,found 444.2199.
Ethyl
2-(1-cyclopropyl-3,3-difluoro-4-oxo-4-(pyrrolidin-1-yl)butyl)cyclohept-1-ene-1-carboxylate(37)
1H-NMR(400MHz,CDCl3):δ＝3.63(d,J＝9.3,5H),3.48(t,J＝6.9,2H),2.56(td,J＝9.1,5.2,1H),2.48–2.23(m,6H),1.96–1.88(m,2H),1.87–1.77(m,3H),1.74–1.37(m,5H),1.22(s,2H),0.85–0.74(m,1H),0.55–0.32(m,2H),0.31–0.22(m,2H).13C-NMR(100MHz,CDCl3):δ＝170.9,162.5(t,2JC-F＝30.1),152.8,131.3,118.9(t,1JC-F＝252.1),51.3,47.6,46.8(t,3JC-F＝6.8),42.1(t,4JC-F＝3.3),37.0(t,2JC-F＝22.4),32.6,30.9,29.8,27.2,26.7,26.6,26.2,23.4,14.8,6.1,4.3.19F-NMR(376MHz,CDCl3):δ＝-100.18(d,J＝277.2),-101.98(d,J＝277.3).HR-MS(EI)m/z calcd for C21H31F2NO3[M+H+]384.2345,found 384.2347.
Ethyl(Z)-4-cyclopropyl-6,6-difluoro-3-methyl-7-oxo-7-(piperidin-1-yl)-2-(2-(thiophen-2-yl)ethyl)hept-2-enoate(38)
1H-NMR(400MHz,CDCl3):δ＝7.22(dd,J＝4.8,3.0Hz,1H),6.96(d,J＝4.9Hz,2H),4.17–4.09(m,2H),3.61(dd,J＝10.6,5.0Hz,2H),3.54(dd,J＝10.6,5.0Hz,2H),2.73(t,J＝7.7Hz,2H),2.68–2.62(m,1H),2.61–2.51(m,2H),2.41(ddd,J＝22.7,13.8,6.9Hz,2H),1.68(s,3H),1.65(dd,J＝6.6,3.2Hz,2H),1.61–1.56(m,4H),1.27(d,J＝7.1Hz,3H),0.83–0.76(m,1H),0.58–0.50(m,1H),0.40–0.29(m,2H),0.26(dt,J＝8.9,4.3Hz,1H).13C-NMR(100MHz,CDCl3):δ＝169.9,162.1(t,2JC-F＝29.0Hz),145.0,142.1,128.5,128.1,125.2,120.6,119.4(t,1JC-F＝255.5Hz),60.2,47.0(t,3JC-F＝6.7Hz),44.6,41.8(t,4JC-F＝2.7Hz),37.7(t,2JC-F＝22.4Hz),31.6,29.1,26.7,25.7,24.7,15.4,14.3,14.1,6.2,3.9.19F-NMR(376MHz,CDCl3):δ＝-97.83(d,J＝280.1Hz),-99.13(d,J＝280.1Hz).HR-MS(EI)m/z calcd for C24H33F2NO3S[M+H+]454.2222,found 454.2227.
Ethyl 8-(2,2-difluoro-1-(indolin-1-yl)-7-methyl-1-oxooctan-4-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(39)
1H-NMR(400MHz,CDCl3):δ＝8.19(d,J＝8.3,1H),7.21(t,J＝6.9,2H),7.08(t,J＝7.1,1H),4.38–4.24(m,2H),4.10(qq,J＝10.8,7.1,2H),4.00–3.90(m,4H),3.83–3.74(m,1H),3.17(t,J＝8.3,2H),2.58–2.23(m,6H),1.78–1.69(m,2H),1.56–1.40(m,3H),1.26–1.19(m,4H),1.14–1.04(m,1H),0.87(d,J＝6.6,6H).13C-NMR(100MHz,CDCl3):δ＝168.4,161.6(t,2JC-F＝30.3),147.2,142.9,131.8,127.6,125.1,124.7,124.4,119.3(t,1JC-F＝255.4),118.0,107.5,64.6,64.6,60.3,48.1(t,3JC-F＝8.0),37.4,37.3(t,2JC-F＝22.0),36.3,35.0,31.7,30.8,28.8,28.2,23.9,22.8,22.6,14.3.19F-NMR(376MHz,CDCl3):δ＝-101.27(d,J＝281.1),-102.05(d,J＝280.9).HR-MS(EI)m/z calcd for C28H37F2NO5[M+H+]506.2713,found506.2717.
Ethyl 2-{1-[3,4-dihydroquinolin-1(2H)-yl]-1,1-difluoro-6-methylheptan-3-yl}-5,5-dimethylcyclohex-1-ene-1-carboxylate(40)
1H-NMR(400MHz,CDCl3):δ＝6.93(d,J＝3.0Hz,1H),6.85(d,J＝9.0Hz,1H),6.73(dd,J＝9.0,3.0Hz,1H),4.17(q,J＝7.1Hz,2H),4.01–3.92(m,6H),3.75(s,3H),3.71(dd,J＝10.2,4.3Hz,1H),2.53(s,2H),2.36(t,J＝7.0Hz,2H),2.31–2.20(m,2H),2.00–1.89(m,2H),1.86–1.68(m,8H),1.65–1.60(m,2H),1.56–1.46(m,2H),1.42(dd,J＝14.2,6.9Hz,2H),1.26(d,J＝7.1Hz,3H).13C-NMR(100MHz,CDCl3):δ＝184.5,170.1,162.9(t,2JC-F＝29.7Hz),144.3,134.5,134.2,132.9,132.5,128.8,128.7,127.1,126.8,126.7,126.7,126.6,126.3,126.2,119.6(t,1JC-F＝255.2Hz),60.2,47.3(t,3JC-F＝7.5Hz),45.7,43.5(t,3JC-F＝7.0Hz),41.8,41.0,38.6,37.7(td,3JC-F＝21.9,7.2Hz),36.6,35.2,35.0,31.9,29.6,28.6,28.4,28.2,28.1,28.0,22.9,22.6,21.8,14.4,14.4.19F-NMR(376MHz,CDCl3):δ＝-99.04(dd,J＝279.3,11.9Hz),-100.02(dd,J＝279.3,120.4Hz).HR-MS(EI)m/z calcdfor C28H41F2NO2[M+H+]462.3178,found 462.3175.
Ethyl 2-(3,3-difluoro-8-methyl-1-(triisopropylsilyl)non-1-yn-5-yl)cyclohex-1-ene-1-carboxylate(41)
1H-NMR(400MHz,CDCl3):δ＝4.16(qd,J＝7.1,0.9,2H),3.50–3.30(m,1H),2.32–1.93(m,5H),1.66–1.32(m,8H),1.28(t,J＝7.1,3H),1.08(d,J＝2.1,23H),0.85(dd,J＝6.6,2.5,6H).13C-NMR(100MHz,CDCl3):δ＝169.9,145.0,127.4,113.8(t,1JC-F＝233.6),99.8(t,2JC-F＝38.8),89.5(t,3JC-F＝5.4),60.2,42.8(t,2JC-F＝25.4),37.0,36.6,30.7,28.3,27.3,24.5,23.0,22.5,22.4,22.3,18.6,14.4,11.1.19F-NMR(376MHz,CDCl3):δ＝-78.99(d,J＝272.0),-82.30(d,J＝272.0).HR-MS(EI)m/z calcd for C28H48F2O2Si[M+H+]483.3464,found483.3461.
Ethyl 2-(3,3-difluoro-8-methylnon-1-yn-5-yl)-5,5-dimethylcyclohex-1-ene-1-carboxylate(42)
1H-NMR(400MHz,CDCl3):δ＝4.22–4.10(m,2H),3.60–3.43(m,1H),2.73(t,J＝5.0,1H),2.31–1.95(m,6H),1.53–1.40(m,2H),1.35(t,J＝6.5,2H),1.29(t,J＝7.1,3H),1.25–0.98(m,3H),0.92(d,J＝5.8,6H),0.86(dd,J＝6.6,2.6,6H).13C-NMR(100MHz,CDCl3):δ＝169.9,143.3,127.0,114.1(t,1JC-F＝233.9),76.9(t,2JC-F＝40.5),75.3(t,3JC-F＝6.8),60.2,42.5(t,2JC-F＝24.7),41.0,36.5,34.9,31.3,28.7,28.6,28.2,27.8,22.9,22.6,21.8,14.4.19F-NMR(376MHz,CDCl3):δ＝-80.89(d,J＝275.6),-82.17(d,J＝275.0).HR-MS(EI)m/z calcd for C21H32F2O2[M+H+]355.2443,found 355.2447.
Ethyl 2-(1-(1,3-dioxan-2-yl)-5,5-difluoro-7-(triisopropylsilyl)hept-6-yn-3-yl)cyclohex-1-ene-1-carb oxylate(43)
1H-NMR(400MHz,CDCl3):δ＝4.48(t,J＝4.9,1H),4.18–4.11(m,2H),4.10–4.01(m,2H),3.72(td,J＝12.2,2.5,2H),3.57–3.46(m,1H),2.35–1.96(m,7H),1.70–1.42(m,9H),1.26(t,J＝7.1,3H),1.10–1.05(m,21H).13C-NMR(100MHz,CDCl3):δ＝169.6,144.7,127.7,113.5(t,1JC-F＝233.7),102.3,99.8(t,2JC-F＝38.8),89.5(t,3JC-F＝5.5),67.0,60.2,42.8(t,2JC-F＝25.6),36.2,33.1,27.2,27.1,26.0,24.3,22.3,22.2,18.6,14.4,11.0.19F-NMR(376MHz,CDCl3):δ＝-79.98(d,J＝272.1),-82.83(d,J＝272.1).HR-MS(EI)m/z calcdfor C29H48F2O4Si[M+H+]527.3363,found 527.3366.
tert-Butyl 4-(benzyloxy)-4-(5-(2-(ethoxycarbonyl)-4,4-dimethylcyclohex-1-en-1-yl)-3,3-difluorohept-1-yn-1-yl)piperidine-1-carboxylate(44)
1H-NMR(400MHz,CDCl3):δ＝7.37–7.29(m,5H),4.64(s,2H),4.13(dtt,J＝10.8,7.3,3.7,2H),3.47(dddd,J＝24.9,12.6,10.5,3.5,5H),2.29–1.96(m,9H),1.92–1.81(m,2H),1.56(dd,J＝14.0,6.5,1H),1.46(s,9H),1.36(t,J＝5.6,2H),1.25(t,J＝7.1,3H),0.92(s,6H),0.83(t,J＝7.4,3H).13C-NMR(100MHz,CDCl3):δ＝169.6,154.7,143.8,138.3,128.5,127.8,127.8,126.9,114.5(t,1JC-F＝234.1),86.9(t,3JC-F＝6.5),80.7(t,2JC-F＝40.7),79.9,72.1,66.3,60.2,42.5(t,2JC-F＝25.1),40.9,37.9,34.9,28.6,28.4,28.1,26.3,22.1,14.4,12.0.19F-NMR(376MHz,CDCl3):δ＝-79.06(d,J＝272.8),-81.94(d,J＝272.8).HR-MS(EI)m/z calcd for C35H49F2NO5[M+H+]602.3652,found 602.3657.
Ethyl
2-(2,2-difluoro-7-methyl-1-(tosyloxy)octan-4-yl)cyclopent-1-ene-1-carboxylate(45)
1H-NMR(400MHz,CDCl3):δ＝7.79(d,J＝8.3,2H),7.35(d,J＝8.1,2H),4.23–4.09(m,4H),3.85–3.69(m,1H),2.64–2.53(m,2H),2.45(s,3H),2.43–2.27(m,2H),2.13–1.92(m,2H),1.82–1.73(m,2H),1.51–1.31(m,3H),1.27(t,J＝7.1,3H),1.13–0.90(m,2H),0.83(dd,J＝6.6,0.8,6H).13C-NMR(100MHz,CDCl3):δ＝166.2,159.1,145.4,132.4,130.1,129.7,128.2,120.8(t,1JC-F＝244.1),68.1(t,2JC-F＝35.1),59.9,37.2(t,2JC-F＝22.5),36.3,33.8,32.7,32.5(t,3JC-F＝3.7),32.3,27.9,22.8,22.4,21.8,21.7,14.4.19F-NMR(376MHz,CDCl3):δ＝-101.96(d,J＝257.8),-103.27(d,J＝257.8).HR-MS(EI)m/z calcdfor C24H34F2O5S[M+H+]473.2168,found 473.2172.
Ethyl 8-(1-cyclopropyl-3-(diethoxyphosphoryl)-3,3-difluoropropyl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(46)
1H-NMR(400MHz,CDCl3):δ＝4.30–4.19(m,4H),4.12(q,J＝7.1,2H),4.03–3.92(m,4H),3.10(dd,J＝16.5,7.2,1H),2.62–2.14(m,6H),1.79–1.68(m,2H),1.36(t,J＝7.1,6H),1.26–1.22(m,3H),0.89–0.74(m,1H),0.62–0.34(m,2H),0.28(pd,J＝9.2,5.0,2H).
13C-NMR(100MHz,CDCl3):δ＝168.1,147.9,123.1,119.6(t,1JC-F＝261.1),107.5,64.6,64.6,60.4,39.5,39.4,37.3,36.6(t,2JC-F＝20.0),36.4(t,2JC-F＝20.1),30.9,27.2,24.9,16.6,16.5,15.2,14.3,6.6,4.0.19F-NMR(376MHz,CDCl3):δ＝-112.54(qd,J＝296.5,108.5,2F).HR-MS(EI)m/z calcd for C21H33F2O7P[M+H+]467.2005,found 467.2008.
Ethyl
8-(1-(benzo[d]oxazol-2-yl)-1,1-difluoro-6-methylheptan-3-yl)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate(47)
1H-NMR(400MHz,CDCl3):δ＝7.79(d,J＝7.4,1H),7.59(d,J＝7.6,1H),7.47–7.37(m,2H),4.03–3.83(m,7H),2.73–2.43(m,2H),2.42–2.20(m,4H),1.72–1.63(m,2H),1.55–1.40(m,3H),1.22–1.15(m,4H),1.07(ddd,J＝18.2,12.5,6.0,1H),0.85(dd,J＝6.6,0.7,6H).13C-NMR(100MHz,CDCl3):δ＝168.0,158.3(t,2JC-F＝33.6),150.7,146.5,140.2,126.8,125.3,124.9,121.3,116.8(t,1JC-F＝242.7),111.5,107.3,64.6,64.5,60.3,39.3(t,2JC-F＝22.8),37.3,36.2,35.1,31.6,30.7,28.2,23.9,22.8,22.6,14.2.19F-NMR(376MHz,CDCl3):δ＝-96.70(d,J＝275.2),-98.46(d,J＝275.2).HR-MS(EI)m/z calcdfor C26H33F2NO5[M+H+]478.2400,found478.2404.
Ethyl 2-[1-(1,3-dioxan-2-yl)-5,5,6,6,7,7,8,8,8-nonafluorooctan-3-yl]-5,5-dimethylcycloh ex-1-ene-1-carboxylate(48)
1H-NMR(400MHz,CDCl3):δ＝4.51(t,J＝3.4Hz,1H),4.17(q,J＝7.1Hz,2H),4.08(dd,J＝11.3,3.8Hz,2H),3.74(td,J＝12.1,2.3Hz,2H),3.69–3.60(m,1H),2.33–2.16(m,1H),2.16–1.96(m,6H),1.68–1.47(m,4H),1.40–1.33(m,2H),1.32–1.29(m,1H),1.27(t,J＝7.1Hz,3H),0.92(s,3H),0.91(s,3H).13C-NMR(100MHz,CDCl3):δ＝169.5,142.2,127.8,102.0,67.0,67.0,60.4,40.9,34.9,34.0,33.6(t,2JC-F＝21.2Hz),32.8,28.5,28.4,28.1,27.8,25.9,21.6,14.3.19F-NMR(376MHz,CDCl3):δ＝-81.06(ddd,J＝13.6,6.8,3.5Hz),-111.18–-118.07(m),-124.59(dd,J＝20.2,10.0Hz),-125.88(ddd,J＝24.5,15.3,6.5Hz).HR-MS(EI)m/z calcd for C23H31F9O4[M+H+]543.2151,found 543.2148.
Ethyl(Z)-4-[2-(1,3-dioxan-2-yl)ethyl]-6,6,7,7,8,8,9,9,9-nonafluoro-3-methyl-2-[2-(thiop hen-2-yl)ethyl]non-2-enoate(49)
1H-NMR(400MHz,CDCl3):δ＝7.25–7.16(m,1H),6.94(d,J＝4.1Hz,2H),4.51(t,J＝4.6Hz,1H),4.18(q,J＝7.1Hz,2H),4.08(dd,J＝11.2,4.5Hz,2H),3.74(td,J＝12.2,2.3Hz,2H),3.64–3.44(m,1H),2.78–2.68(m,2H),2.62–2.53(m,2H),2.24–1.89(m,3H),1.64–1.57(m,2H),1.55(s,3H),1.53–1.32(m,3H),1.28(t,J＝7.1Hz,3H).13C-NMR(100MHz,CDCl3):δ＝169.5,142.0,141.9,131.0,128.5,125.4,120.7,102.0,67.0,67.0,60.5,35.3,33.7(t,2JC-F＝21.2Hz),32.7,31.7,29.0,27.4,25.9,14.3,12.7.19F-NMR(376MHz,CDCl3):δ＝-81.06(ddd,J＝9.9,8.7,3.0Hz),-107.27–-117.07(m),-124.60(dd,J＝20.4,10.0Hz),-125.88(ddd,J＝20.9,9.5,5.0Hz).HR-MS(EI)m/z calcd for C24H29F9O4S[M+H+]585.1716,found585.1708.
本发明研究了一种新型烷基锌试剂在烯烃双官能团化反应中的底物适用性和官能团兼容性等方面的考察，在该反应体系中表现出广泛的底物适用性和优秀的官能团兼容性，并且可以顺利的进行反应放大至克级规模，反应效率基本保持不变。该烷基锌试剂通过无机盐活化策略拥有良好化学反应活性，该试剂可以进一步应用于具有药理学活性的天然产物以及药物分子的结构修饰，从而也进一步说明了该类烷基锌试剂，以及该合成方法学在有机化学，生物化学，药物化学领域具有潜在的应用价值。具体反应成果如图4-6所示。
显然，上述实施例仅仅是为清楚地说明所作的举例，并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引申出的显而易见的变化或变动仍处于本发明创造的保护范围之中。

Claims (10)

1.一类烷基锌试剂，其特征在于，所述烷基锌试剂的结构通式：R-ZnOPiv·Mg(OPiv)Br；其中，R选自链状烷基、环状烷基和取代烷基中的一种或多种。
2.权利要求1所述的烷基锌试剂的制备方法，其特征在于，包括以下步骤：
(1)在有机溶剂中，将烷基溴代物、镁与催化剂混合反应，得到格式试剂；
(2)向步骤(1)所得格式试剂中加入特戊酸锌混合反应，得到所述的烷基锌试剂。
3.根据权利要求2所述的制备方法，其特征在于，步骤(1)中，所述烷基溴代物选自链状烷基溴代物、环状烷基溴代物和取代烷基溴代物中的一种或多种。
4.根据权利要求2所述的制备方法，其特征在于，步骤(1)中，所述催化剂为碘和/或锂盐。
5.根据权利要求2所述的制备方法，其特征在于，步骤(2)中，所述格式试剂与特戊酸锌的摩尔比为1:1.2-1:1.5。
6.权利要求1所述的烷基锌试剂在烯烃双官能团化反应中的应用。
7.权利要求1所述的烷基锌试剂在制备烷基取代的烷基二氟试剂中的应用。
8.根据权利要求7所述的应用，其特征在于，所述烷基取代的烷基二氟试剂的制备包括以下步骤：
在有机溶剂中，将
Figure FDA0004060912320000011
与R-ZnOPiv·Mg(OPiv)Br在催化剂作用下混合反应，得到所述烷基取代的烷基二氟试剂，其中X＝Br、I；
其中，R1选自酯基、烷基、炔基、酰胺、苯并恶唑、磷酸二乙酯和全氟取代烷基中的一种或多种；R选自链状烷基、环状烷基和取代烷基中的一种或多种；R2和R3均独立的选自取代烷基；R4选自酯基。
9.根据权利要求8所述的应用，其特征在于，所述
Figure FDA0004060912320000021
与R-ZnOPiv·Mg(OPiv)Br的摩尔比为1:1:1.5-1:2:3，其中X＝Br、I。
10.根据权利要求8所述的应用，其特征在于，所述催化剂选自Co、Fe、Cr、Ni和Cu中的一种或多种。
CN202310058778.7A 2023-01-17 2023-01-17 一类烷基锌试剂及其制备方法与应用 Active CN116003445B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202310058778.7A CN116003445B (zh) 2023-01-17 2023-01-17 一类烷基锌试剂及其制备方法与应用
PCT/CN2023/078633 WO2024152408A1 (zh) 2023-01-17 2023-02-28 一类烷基锌试剂及其制备方法与应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310058778.7A CN116003445B (zh) 2023-01-17 2023-01-17 一类烷基锌试剂及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN116003445A true CN116003445A (zh) 2023-04-25
CN116003445B CN116003445B (zh) 2025-04-25

Family

ID=86035522

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310058778.7A Active CN116003445B (zh) 2023-01-17 2023-01-17 一类烷基锌试剂及其制备方法与应用

Country Status (2)

Country Link
CN (1) CN116003445B (zh)
WO (1) WO2024152408A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146689A1 (en) * 2015-03-19 2016-09-22 Ludwig-Maximilians-Universität München Organozinc reagents and processes for preparing and using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2620376C2 (ru) * 2010-12-22 2017-05-25 Людвиг-Максимилианс-Университэт Мюнхен Цинкорганические комплексы, способы их получения и применение

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146689A1 (en) * 2015-03-19 2016-09-22 Ludwig-Maximilians-Universität München Organozinc reagents and processes for preparing and using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIE LIN ET AL.: "Salt-stabilized alkylzinc pivalates: versatile reagents for cobalt-catalyzed selective 1, 2-dialkylation", CHEM. SCI., vol. 14, 31 December 2023 (2023-12-31), pages 8672 - 8680 *
MARIO ELLWART ET AL.: "Preparation of Solid, Substituted Allylic Zinc Reagents and Their Reactions with Electrophiles", ANGEW. CHEM. INT. ED., vol. 54, 31 December 2015 (2015-12-31), pages 10662 - 10665, XP072077379, DOI: 10.1002/anie.201504354 *
SEBASTIAN BERNHARDT ET AL.: "Preparation of Solid Salt-Stabilized Functionalized Organozinc Compounds and their Application to Cross-Coupling and Carbonyl Addition Reactions", ANGEW. CHEM. INT. ED., vol. 50, 31 December 2011 (2011-12-31), pages 9205 - 9209, XP055137679, DOI: 10.1002/anie.201104291 *
XINYI CHENG ET AL.: "Organozinc pivalates for cobalt-catalyzed difluoroalkylarylation of alkenes", NATURE COMMUNICATIONS, vol. 12, 31 December 2021 (2021-12-31), pages 4366 - 4375 *

Also Published As

Publication number Publication date
CN116003445B (zh) 2025-04-25
WO2024152408A1 (zh) 2024-07-25

Similar Documents

Publication Publication Date Title
TW200424148A (en) Azide free process for preparing neuraminidase inhibitors r6
WO2024152408A1 (zh) 一类烷基锌试剂及其制备方法与应用
CN101967075B (zh) 一种利用3-芳基-2,3-二溴丙酸合成端炔化合物的方法
CN103664585B (zh) 一种三氟甲基羰基化合物的制备方法
JP2019147829A (ja) ５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN110156815A (zh) 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法
CN101891731A (zh) 一种奥洛他定e构型异构体的合成方法
CN109678900B (zh) 一种磺胺衍生物及其制备方法与应用
CN109942553B (zh) 一种手性3,4,6-三取代四氢2h-吡喃-2-酮化合物的合成及其转化方法
EP3606907B1 (en) Racemic beta-aminosulfone compounds
CN106243007B (zh) 一种三氟甲基取代的杂环化合物及其制备方法
RU2818999C1 (ru) Способ получения интермедиата урацилового соединения, содержащего изоксазолин
CN105712956B (zh) 一种温和高效的多官能团取代环氧类化合物的制备方法
KR20130110017A (ko) 산쇼올류의 제조 방법
CN115057882B (zh) 一类多取代烯基锡试剂及其立体选择性制备与应用
JPH0959290A (ja) フェロセニルジフェニルホスフィン誘導体、該配位子金属錯体によるヒドロシリル化
JPH0555489B2 (zh)
JP2023155765A (ja) アミド化合物の製造方法
KR100645371B1 (ko) 두 고리형 테트라하이드로퓨란 화합물과 이의 제조방법
CN105884770A (zh) 1，3-二取代中氮茚衍生物的制备方法
JP4051967B2 (ja) ホスホノジヒドロピラン誘導体の製造法
JP2021098666A (ja) ｇｅｍ−ジフルオロシクロプロペンテトラフルオロスルファニルアレーン化合物
JP4591778B2 (ja) α，β，γ−置換シクロペンタノン誘導体の製造法
Fletcher 2 Synthetic methods Part (iv) Heteroatom methods
Mathieson A flexible one-step synthesis of dienamides: approaches towards a total synthesis of the Crocacins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant